SourceBio International PLC COVID testing contract for elite rugby in England (4013R)
08 March 2021 - 6:00PM
UK Regulatory
TIDMSBI
RNS Number : 4013R
SourceBio International PLC
08 March 2021
SourceBio International plc
("SourceBio", the "Company" or the "Group")
COVID-19 testing contract for elite rugby in England
SourceBio testing the England Rugby squad as part of the Six
Nations tournament
RFU testing services to cover Gallagher Premiership Rugby and
Greene King IPA Championship testing
SourceBio International plc (AIM: SBI), the international
provider of integrated state-of-the-art laboratory services and
products , announces that it has entered into an agreement with the
Rugby Football Union ("RFU") and Premiership Rugby Limited to
provide COVID-19 screening testing services for elite rugby in
England.
Under the agreement SourceBio will provide COVID-19 testing
services to England Rugby Senior Men's squad and support staff and
to all 12 Premiership Rugby clubs players and staff. In addition,
the RFU is also looking to roll-out this testing service to RFU
Championship clubs who will be able to use this agreement to access
the services provided by SourceBio.
SourceBio will provide COVID-19 testing to players and staff
around training schedules and ahead of match days. Third party
healthcare professionals sourced by SourceBio will take swabs from
individuals and samples are then couriered to the Company's ISO
15189 accredited laboratory facility in Nottingham for PCR Testing.
Test results are turned around in less than 24 hours.
SourceBio has processed more than 1,000,000 COVID-19 antigen
RT-PCR tests for the DHSC and the NHS, Private Hospital Groups and
Commercial customers since first offering its service in May
2020.
Jay LeCoque, Executive Chairman, commented: "We are very pleased
to support elite rugby return to play protocols using our
state-of-the-art laboratories to allow elite rugby in England to
continue to safely operate within current social distancing
measures. We have been at the forefront of COVID-19 testing
programmes since the beginning of the pandemic, supporting the NHS
and private healthcare groups, but also helping many of our
commercial clients to maintain a safe working environment and
helping businesses to get back on track."
Contacts:
SourceBio International plc www.sourcebiointernational.com
Jay LeCoque, Executive Chairman Via Walbrook PR
Tony Ratcliffe, Chief Financial Officer
Liberum (Nominated Adviser and Broker) Tel: 020 3100 2000
Bidhi Bhoma
Euan Brown
William Hall
Walbrook PR Limited Tel: 020 7933 8780 or sourcebio@walbrookpr.com
Paul McManus / Sam Allen Mob: 07980 541 893 / 07748
651 727
About SourceBio International plc
www.sourcebiointernational.com
SourceBio is a leading international provider of integrated
state-of-the-art laboratory services and products clients in the
healthcare, clinical, life science research and biopharma
industries, with a focus on improving patient diagnosis, management
and care. Group revenues are derived from four core businesses
areas:
-- Infectious Disease Testing - a range of COVID-19 testing
services for the Department of Health and Social Care (DHSC), the
NHS, Private Healthcare groups and Commercial enterprises.
Utilising various technologies (RT-qPCR, LamPore and LAMP)
SourceBio offers both screening and gold standard COVID-19 testing
and operates under the ISO: 15189 accreditation required by the
DHSC for COVID-19 test services. SourceBio offers employee testing
solutions to industry, home testing kits (including 'Fit to Fly'
and 'Test to Release' approved tests) and operates Mobile Testing
Unit laboratories to support event and venue testing.
-- Healthcare Diagnostics - histopathology and clinical
diagnostic services for the NHS and private healthcare across the
UK and Ireland.
-- Genomics - DNA sequencing services for pharmaceutical and
biotechnology companies, academia, contract research organisations
(CROs) and other research groups in the UK, Europe and North
America.
-- Stability Storage - shelf-life testing services and equipment
for pharmaceutical and biotechnology companies, contract
manufacturers and analytical testing companies from around the
world but primarily in the UK, Ireland and the USA.
More details on Group operations can be found here:
www.sourcebioscience.com
SourceBio International plc (SBI.L) is listed on the AIM market
of the London Stock Exchange.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
AGRGZGGFLKKGMZM
(END) Dow Jones Newswires
March 08, 2021 02:00 ET (07:00 GMT)
Sourcebio (LSE:SBI)
Historical Stock Chart
From Nov 2024 to Dec 2024
Sourcebio (LSE:SBI)
Historical Stock Chart
From Dec 2023 to Dec 2024